Next Article in Journal
Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma
Next Article in Special Issue
Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation
Previous Article in Journal
Circulating MicroRNA Biomarkers for Lung Cancer Detection in East Asian Populations
Previous Article in Special Issue
BRCA2 and Other DDR Genes in Prostate Cancer
Open AccessReview

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Division of Medical Oncology & Hematology, Princess Margaret Cancer Center, Toronto, ON M5G 2M9, Canada
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 416; https://doi.org/10.3390/cancers11030416
Received: 5 February 2019 / Revised: 13 March 2019 / Accepted: 18 March 2019 / Published: 23 March 2019
(This article belongs to the Special Issue BRCA Mutations and Cancer)
High grade serous ovarian cancer (HGSOC) is the most common epithelial ovarian cancer, harbouring more than 20% germline or somatic mutations in the tumour suppressor genes BRCA1 and BRCA2. These genes are involved in both DNA damage repair process via homologous recombination (HR) and transcriptional regulation. BRCA mutation confers distinct characteristics, including an increased response to DNA-damaging agents, such us platinum chemotherapy and poly-ADP ribose polymerase inhibitors (PARPi). However, several mechanisms of resistance to these agents have been described, including increased HR capacity through reverse BRCA mutations, non-homologous end-joint (NHEJ) repair alterations and drug efflux pumps. Current treatments of ovarian cancer including surgery, chemotherapy, targeted treatment and maintenance strategies, as well as resistance mechanisms will be reviewed, focusing on future trends with respect to BRCA mutation carriers. View Full-Text
Keywords: ovarian cancer; BRCA mutation; homologous recombination; treatment; platinum; PARP inhibitor; resistance ovarian cancer; BRCA mutation; homologous recombination; treatment; platinum; PARP inhibitor; resistance
Show Figures

Figure 1

MDPI and ACS Style

Madariaga, A.; Lheureux, S.; Oza, A.M. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers 2019, 11, 416.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop